Nuclidium
Manufacturing · Switzerland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Bäumleingasse Im Erasmushaus 18, Basel, ...Website
www.nuclidium.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Nuclidium
NUCLIDIUM AG is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – NUCLIDIUM is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. The company's operations in Switzerland and Germany combine innovative chemistry, deep clinical expertise, and strategic manufacturing capabilities to deliver scalable, accessible, and clinically superior theranostic solutions to patients worldwide. NUCLIDIUM is committed to expanding the reach and efficacy of radiotheranostics, including addressing critical unmet medical needs in oncology and women’s health.Explore more
Nuclidium Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nuclidium your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Nuclidium is spiking on competitors!
Earning: See what the market has to say on Nuclidium recently announced quarterly report
Product Launch: Get notified when Nuclidium launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Nuclidium
Click to see if Nuclidium had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Nuclidium has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Nuclidium, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Nuclidium has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Nuclidium as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Nuclidium is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nuclidium is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nuclidium.
Nuclidium financials insights
Gather financial insights about Nuclidium, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$2.9M
2025
Series B
$98.5M
Nuclidium Tech Stack
A closer look at the technologies used by Nuclidium
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Healthcare Technology
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Executive Move
Executive Moves, Board of Directors
Nuclidium News & Media
'Copper theranostics bring diagnosis and treatment together in a highly effective way' - VC Magazin
Dr Leila Jaafar-Thiel, CEO of Nuclidium, explains how the company’s copper-based radiotheranostic approach will become a milestone in precision oncology for an improved individual treatment of patients.NUCLIDIUM Announces Closing of Series B Extension Bringing Total Round to CHF 105 Million
NUCLIDIUM announced a CHF 26.4 million extension led by existing investors to accelerate clinical development of NU101 and NU201 radiotheranostic programs.NUCLIDIUM Announces Issuance of New U.S. Patent Covering its 61Cu-based Radiodiagnostic Program for PSMA-positive Prostate Cancer
Patent for composition of matter & methods of use of high-radiopure diagnostic ⁶¹Cu-NU101 & combination use w/ 67Cu- therapeutic in PSMA+ prostate cancerNUCLIDIUM Presents Positive Phase I/II Results for First Copper-based PET Diagnostic in Neuroendocrine Tumors at EANM Congress 2025
Basel, Switzerland, October 08, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced positive clinical data from the ongoing Phase I/II trial (NCT06455358) evaluating its novel copper-radiolabeled PET tracer, 61Cu-TraceNetTM ([61Cu]Cu-NODAGA-LM3) in patients with SSTR-positive gastroenteropancreatic and bronchopulmonary neuroendocrine tumors (GEP & BP-NETS). Principal investigator Dr. Guillaume Nicolas, Depu
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nuclidium
Sign Up For FreeTo access detailed company insights
NUCLIDIUM AG is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – NUCLIDIUM is creating a differentiated platform with the potential to overcome exist... Read More
